H.C. Wainwright Keeps Buy on Madrigal Pharmaceuticals (MDGL) on Strong Rezdiffra Uptake and F2/F3 MASH Patient Data

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the high short interest stocks to buy right now. On November 21, H.C. Wainwright raised the firm’s price target on Madrigal Pharmaceuticals to $620 from $568 and maintained a Buy rating. H.C. Wainwright increased its assumptions for Rezdiffra penetration after consulting with 6 key opinion leaders/KOLs. They reported real-world uptake of the drug among patients with metabolic dysfunction-associated steatohepatitis/MASH who have F2/F3 liver fibrosis. Despite competitive pressure from weight loss medications, the firm noted that the KOLs view Rezdiffra as an effective, liver-directed, oral backbone therapy that offers broader expansion possibilities based on forthcoming F4c data.

Earlier in its Q3 2025 earnings call, Madrigal Pharmaceuticals reported significant commercial momentum for its product, Rezdiffra. The company achieved net sales of $287.3 million for the quarter, marking a 35% sequential increase. The total number of patients on Rezdiffra therapy has surpassed 29,500, up from over 23,000 in the previous quarter, with more than 10,000 healthcare providers having prescribed the medication.

H.C. Wainwright Keeps Buy on Madrigal Pharmaceuticals (MDGL) on Strong Rezdiffra Uptake and F2/F3 MASH Patient Data

Madrigal has made substantial progress in securing market access, achieving broad first-line access with no step edit requirements in its payer contracting for 2026. Adherence rates for Rezdiffra are stable, similar to other well-tolerated oral medications, ranging from 60% to 70%. Madrigal is also focused on expanding its global presence, having successfully launched Rezdiffra in Germany following European approval. However, the impact of the EU launch on 2026 growth is expected to be modest, with the majority of growth still driven by the US market.

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is a biopharmaceutical company that delivers novel therapeutics for metabolic dysfunction-associated steatohepatitis/MASH in the US.

While we acknowledge the potential of MDGL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MDGL and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.